Nucleix Ltd.

Nucleix is a liquid biopsy company focused on revolutionizing cancer treatment through early detection. They utilize a PCR-based epigenetic approach, specifically targeting DNA methylation patterns, to detect early-stage and recurring cancer. Their flagship product, EpiCheck, is a non-invasive platform technology designed to deliver highly accurate and sensitive results. This platform has been adapted for various cancer types, with the most advanced being Bladder EpiCheck, now cleared by the FDA for bladder cancer recurrence monitoring in the United States, and Lung EpiCheck, currently under clinical development for early-stage lung cancer detection.

Nucleix operates globally, with offices in San Diego, California, and Rehovot, Israel. They have established partnerships with leading medical centers, organizations, and laboratories worldwide, including the Cleveland Clinic, Radboud UMC, and Duke Hospital. Their commitment to accessibility is reflected in their website's user-friendly design and adherence to WCAG 2.1 Level AA success criteria, ensuring inclusivity for all users.

Nucleix is a liquid biopsy company dedicated to improving patient health through early cancer detection. They leverage PCR-based epigenetics and methylation-based identification to create non-invasive tests that provide highly accurate and sensitive results, aiming to detect cancer at its earliest stages for more effective treatment options. Their EpiCheck® platform offers a seamless testing experience for both patients and the healthcare system, revolutionizing cancer treatment through early detection.

Nucleix fosters a collaborative and innovative culture focused on improving patient health through its liquid biopsy technology. They emphasize teamwork, building strong partnerships with leading medical centers and organizations worldwide, and strive for continuous improvement in their technology and services. Their dedication to delivering highly accurate and sensitive results highlights a commitment to quality and patient-centricity, while their efforts to develop additional assays for other cancers suggest an ambitious and forward-thinking approach.

Nucleix is committed to fostering a diverse, equitable, and inclusive workplace, ensuring equal access to opportunities for all individuals, including those with disabilities. They strive to create an environment where all voices are heard and valued, and actively promote diversity across their teams. Their website highlights their commitment to accessibility, with a dedicated accessibility policy outlining their efforts to comply with relevant regulations and best practices.